Wang, Y., Zhong, W., Salam, A., Tarning, J., Zhan, Q., Huang, J., . . . Cao, B. (2020). Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. Elsevier.
Chicago Style (17th ed.) CitationWang, Y., et al. Phase 2a, Open-label, Dose-escalating, Multi-center Pharmacokinetic Study of Favipiravir (T-705) in Combination with Oseltamivir in Patients with Severe Influenza. Elsevier, 2020.
MLA引文Wang, Y., et al. Phase 2a, Open-label, Dose-escalating, Multi-center Pharmacokinetic Study of Favipiravir (T-705) in Combination with Oseltamivir in Patients with Severe Influenza. Elsevier, 2020.
警告:這些引文格式不一定是100%准確.